SHX001 Storage Temperature –70 C
Total Page:16
File Type:pdf, Size:1020Kb
MISSION® LentiExpress™ Human Kinases Catalog Number SHX001 Storage Temperature –70 C TECHNICAL BULLETIN Product Description The shRNA sequences are delivered to cells by LentiExpress technology enables lentiviral shRNA replication incompetent lentiviral particles. Unlike screens in an easy, convenient and economical format. murine-based MMLV or MSCV retroviral systems, The technology employs controls and clones of the lentiviral-based particles permit efficient infection and MISSION TRC shRNA libraries which are used in gene integration of the specific shRNA sequence into specific RNA interference (RNAi) in mammalian cells. differentiated and non-dividing cells, such as neurons and dendritic cells2. Self-inactivating replication The MISSION product line includes lentiviral vector- incompetent lentiviral particles are generated in based RNAi libraries against annotated mouse and producer cells (HEK 293T) by co-transfection with human genes. shRNAs that generate siRNAs compatible packaging plasmids3-4 (Catalog Number intracellularly are expressed from amphotropic lentivirus SHP001). In addition, the lentiviral transduction particles, allowing screening in a wide range of particles are pseudotyped with an envelope G mammalian cell types. In these cells, MISSION shRNA glycoprotein from Vesicular Stomatitis Virus (VSV-G), clones permit rapid, cost efficient loss-of-function and allowing transduction of a wide variety of mammalian genetic interaction screens. cells.5 MISSION LentiExpress Human Kinases is a The lentiviral transduction particles are titered via a p24 pre-arrayed set of lentiviral particles allowing for rapid antigen ELISA assay, and pg/ml of p24 are then and effective whole kinome RNAi screening even in converted to transducing units per ml using a difficult to transfect cells. Protein kinases are among the conversion factor. The conversion can be viewed at: largest and most well studied gene families. Protein www.sigma.com/titer. phosphorylation plays an essential role in intercellular communication in eukaryotic organisms by mediating Screens can be quickly carried out using LentiExpress signal transduction during development, transcription, by simply adding cells of interest into each well of the immune response, metabolism, apoptosis, and cell 96-well plate. Pre-arrayed transduction-ready particles differentiation. Aberrant regulation of kinases plays a allow for rapid lenti-shRNA based screening in a variety causal role in many diseases, and the study of these of mammalian cell types. proteins and their functions will contribute to the discovery and development of new therapeutics. To achieve the best transduction efficiency, especially in hard to transduce cell lines, it is strongly MISSION LentiExpress Human Kinases contains recommended that the MISSION LentiExpress ~3,200 different lentiviruses carrying shRNA sequences Optimization Plate, Catalog No. SHXC01, be used prior targeting ~501 human kinase genes, allowing for quick, to screening. This product is intended for rapid high throughput loss-of-function screens. These kinase determination of the optimal cell number (thus MOI) to genes were chosen based on the 2002 paper by use for LentiExpress assays. Manning, G., et al.,1 and the RNAi Consortium. Each gene is represented by a clone set that consists of ~6 individual constructs, or clones, targeting different regions of the gene sequence. Therefore, a range of knockdown efficiencies can be expected, usually with 1 or more constructs from each gene set being >70%. Each shRNA construct has been cloned and sequence verified to ensure a match to the target gene. 2 Reagents/Components Biosafety Features MISSION LentiExpress Human Kinases consist of forty- The lack of generation of replication competent viral one individual 96-well plates. In each plate, 88 wells particles is an important safety feature of MISSION contain 30 L of shRNA Lentiviral Particles or controls shRNA Lentiviral Particles. Safety features are and 8 wells contain 30 L of media only. A CD contains summarized in Table 1. Users should consult and detailed clone position, RefSeq, locus link, gene observe their own institutional guidelines when working description, gene symbol, clone ID, and hairpin with viral systems. sequence. Table 1. Recommended controls for any shRNA experiment are described in the Control Selection Table that Biosafety Features of Third-Generation Lentiviral follows and are closely aligned with the controls Particles suggested in theNature Cell Biology editorial.6 Feature Result Multi-plasmid No single plasmid contains all the Reagents and equipment required, but not provided approach genes necessary to produce Target cells in culture packaged lentivirus. Resultant Complete growth media particles are replication- Hank’s Balanced Salt Solution, Catalog No. H6648 incompetent. 1x Trypsin-EDTA solution, Catalog No. T3924 SIN 3’ LTR Deletion in U3 portion of 3’ LTR 10% Bleach solution eliminates the promoter-enhancer Hexadimethrine bromide, Catalog No. H9268 region, avoids promoter Puromycin (10mg/ml solution), Catalog No. P9620 interference issues, and further Sterile pipette tips negates the possibility of viral Centrifuge with swinging-plate rotor replication, self-inactivating feature Follow distributor’s instructions for culturing and Elimination of the Removes virulence genes which maintaining the target cell line. It is recommended to majority of lentiviral are not necessary for shRNA use the lowest passage # of cells possible for genes ( vpr, vif, packaging systems transduction experiments. vpu and nef) 5 Chimeric 5’ LTR Reduces the chance of insertional Precautions and Disclaimer oncogenesis, allows for tat This product is for R&D use only, not for drug, independent transcription (tat has household, or other uses. Please consult the Material been implicated in various Safety Data Sheet for information regarding hazards carcinomas). and safe handling practices. Though the lentiviral transduction particles produced Storage/Stability are replication incompetent, it is recommended that After receiving immediately store the product at 70 °C. they be treated as Risk Group Level 2 (RGL-2) Avoid freeze/thaw cycles, as this will severely reduce organisms in laboratory handling.7 Follow all published transduction efficiency. RGL-2 guidelines for laboratory handling and waste decontamination. 3 Representative Plate Layout Procedure Overview Lentiviral particles are provided in a pre-arrayed, Step Description ready-to-use format in 96-well plates. The MISSION Thaw the LentiExpress plates containing LentiExpress Human Kinases consists of 41 plates, 1 viral particles for 10 minutes at room wherein each plate contains up to 80 different kinase- temperature specific clones. Each well is pre-diluted to contain Spin plates at 1000 rpm for 1 minute (if 2 approximately 5,000 lentiviral particles in a single possible) reaction volume of 30 L. In addition to the kinase 3 Remove sealer (important to thaw first) shRNA particles (K), each plate includes negative Seed cells into LentiExpress plates with 4 controls to monitor transduction efficiency: media containing hexadimethrine bromide Change media to fresh media 24 hours post 5 1 2 3 4 5 6 7 8 9 10 11 12 transduction A C K K K K K K K K K K C Add fresh media containing puromycin 48 6 B C K K K K K K K K K K C hours post transduction C N K K K K K K K K K K N Grow cells to optimal confluency to perform 7 D N K K K K K K K K K K N assay of choice E M K K K K K K K K K K M F M K K K K K K K K K K M Note: The appropriate concentration of puromycin for G M K K K K K K K K K K M each cell type will vary. If the appropriate concentration H M K K K K K K K K K K M for the desired cell type is unknown, a titration experiment, or kill curve, must be performed. Typically, Wells A1, A12, B1 and B12 contain MISSION pLKO.1- 210 g/ml are sufficient to kill most untransduced puro Control Transduction Particles (C) Catalog No. mammalian cell types. SHC001V, as a negative control. These “empty vector” particles do not contain an shRNA insert and there is no Puromycin Titration: evidence that they activate the RNAi pathway. These Puromycin titration (kill curve) should be performed wells provide positive controls for efficient transduction when working with a new cell type. 4 since the puromycin resistance gene is expressed 1. Plate 1.6 X 10 cells into wells of a 96-well plate under control of the hPGK promoter (as in the kinase with 120 L fresh medium. clones and other controls). 2. The next day add 500–10,000 ng/ml of puromycin to selected wells. Wells C1, C12, D1 and D12 contain MISSION Non- 3. Examine viability every 2 days. Target shRNA Control Transduction Particles (N), 4. Culture for 3 – 14 days depending on the growth Catalog No. SHC002V. This non-targeting shRNA is a rate of the cell type and the length of time that cells useful negative control that will activate RISC and the would typically be under selection during a normal RNAi pathway, but does not target any known human experimental protocol. Replace the media or mouse genes. containing puromycin every 3 days. The minimum concentration of puromycin that causes complete Wells E1, E12, F1, F12, G1, G12, H1 and H12 do not cell death after the desired time should be used for include shRNA lentiviral particles or control lentiviral that cell type and experiment. particles, but contain 30 µL of media (M) and are Note: Excess puromycin can cause many undesired intended for use as a negative control during the phenotypic responses in most cell types. puromycin selection process. 4 Procedure for each 96-well MISSION LentiExpress 4. Transduction Human Kinase shRNA plate a. Mix the cells and then add 70 L of cell suspension (~1000 cells) to each well in the Day 1: Preparations 96-well plate (making sure the virus is already 1. Prepare container with 10% bleach solution for thawed before adding the cells).